VCYT Company Profile and Key Details

Q: Who are the executives of VCYT?

Mr. Robert BraininExecutive Vice President & Chief Bus. OfficerMs. Rebecca ChambersExecutive Vice President & Chief Financial OfficerDr. Giulia C. Kennedy Ph.D.Global Chief Scientific Officer & Chief Medical OfficerMr. Jonathan WygantVice President & Chief Accounting OfficerMs. Bonnie H. AndersonCo-Founder & DirectorMr. Steven FrenchSenior Vice President & Chief Information OfficerMr. John Walter Hanna Jr.Chief Commercial Officer and GM of Endocrinology, Breast Cancer & LymphomaMs. Annie McGuireExecutive Vice President, Gen. Counsel & Chief People OfficerDr. Fabienne Hermitte Ph.D.Senior Vice President of Global Quality & Regulatory AffairsDr. John Leite Ph.D.Senior Vice President and GM of Pulmonology & Market AccessMs. Corinne DananSenior Vice President and GM of Biopharma & IVD ServicesMs. Tracy MorrisVice President of Global Corporation CommunicationsMs. Beverly Jane Alley CPAVice President & Corporation ControllerMr. Marc A. StapleyChief Executive Officer & Director

NASDAQ : VCYT

Veracyte

$33.15

-0.56-1.66%

At Close 4:00 PM

58.69

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Veracyte, Inc. (VCYT) stock declined over -1.66%, trading at $33.15 on NASDAQ, down from the previous close of $33.71. The stock opened at $33.75, fluctuating between $31.96 and $33.90 in the recent session.

Stock Snapshot

33.71

Prev. Close

2.63B

Market Cap

31.955

Day Low

40.43

P/E Ratio

0.82

EPS (TTM)

0.47

Cash Flow per Share

33.75

Open

79.46M

Number of Shares

33.9

Day High

99.41%

Free Float in %

14.28

Book Value

829.89K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 23, 2026	33.75	33.90	31.96	33.15	853.96K
Apr 22, 2026	33.79	34.05	33.22	33.71	538.42K
Apr 21, 2026	33.49	34.63	33.29	33.51	660.01K
Apr 20, 2026	33.35	33.78	33.08	33.45	386.84K
Apr 17, 2026	34.11	34.56	33.30	33.80	1.18M
Apr 16, 2026	34.00	34.32	32.71	33.03	587.41K
Apr 14, 2026	32.54	34.48	32.42	34.30	504.18K
Apr 13, 2026	31.57	32.75	31.54	32.44	912.15K
Apr 10, 2026	31.27	31.92	30.56	31.09	798.48K
Apr 09, 2026	32.22	32.34	30.99	31.35	510.43K
Apr 08, 2026	33.78	34.09	32.45	32.67	825.78K
Apr 07, 2026	32.09	32.60	31.63	32.15	503.49K
Apr 06, 2026	32.05	32.54	31.80	32.32	411.72K
Apr 02, 2026	31.48	33.18	31.48	32.25	702.9K
Apr 01, 2026	32.31	33.54	32.00	32.40	637.99K
Mar 31, 2026	31.00	32.57	30.74	32.21	1.08M
Mar 30, 2026	30.20	30.71	29.88	30.44	1.33M
Mar 27, 2026	32.39	32.68	29.46	30.01	1.49M
Mar 25, 2026	33.51	34.18	32.53	32.79	609.87K
Mar 24, 2026	33.03	33.36	32.17	32.94	939.67K

Contact Details

South San Francisco, CA 94080

United States

https://www.veracyte.com 650 243 6300

About Company

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Stock Peers

ARGX

-12.16-1.51%

argenx SE$793.22 REGN

-0.78-0.10%

Regeneron Pharmaceuticals, Inc.$746.58 UTHR

0.83+0.14%

United Therapeutics Corporation$574.29 MDGL

1.45+0.27%

Madrigal Pharmaceuticals, Inc.$529.14 VRTX

1.08+0.25%

Vertex Pharmaceuticals Incorporated$437.67 PRAX

-3.55-1.04%

Praxis Precision Medicines, Inc.$337.29 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

2.15+0.70%

Alnylam Pharmaceuticals, Inc.$310.58 KRYS

3.28+1.20%

Krystal Biotech, Inc.$275.94 ASND

-9.24-3.85%

Ascendis Pharma A/S$231.05

Company Overview

Veracyte, Inc. (NASDAQ:VCYT) closed at $33.15 USD, losing -$0.56 (-1.66%) from the previous close of $33.71. The stock is currently mid-range between its 52-week high and low $22.61 and $50.71. With a market capitalization of about $2.63 billion, Veracyte, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.96). Key stats such as the average daily volume over the past year has been around 905.72 thousand shares, in line with its 52-week average. Headquartered in South San Francisco, CA, Veracyte, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marc A. Stapley, the company employs approximately 824 people and listed since October 30, 2013. Veracyte, Inc. operates as a diagnostics company worldwide.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 6.02%, SMA50 -3.47%, SMA200 13.22%). The stock’s 14-day RSI is 54.98 (neutral), while the ATR of 1.7 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -23.59% below its high and over 71.38% above its low. Average 10-day trading volume of 702.27 thousand shares is below the 3-month average of 897.05 thousand, indicating normal recent market interest.

Valuation Metrics

Veracyte, Inc. trades at a P/E ratio of 39.18, slightly above the S&P 500 average, with a price-to-sales ratio of 5.04 and a price-to-book ratio of 1.98 suggesting the stock is closer to book value. The P/FCF stands at 20.69, also below market averages.

Dividend & Fair Value

Veracyte, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $42.56. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 4.03% annually over the next five years. The latest quarter delivered EPS of $0.51. The next quarter is forecast at $0.34. Next year's EPS is expected at $62.14. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 9 Buy ratings, 3 Hold ratings, 0 Sell rating and 3 Strong Sell ratings. Price targets range from $50.00 to $40.00. The high target offers 50.83% upside. The low target suggests 20.66% downside. The mean target is $45.13. This offers 36.14% upside. Veracyte, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 04, 2025, missed forecasts by 59.38%. The prior quarter beat by 41.94%. Over the last six quarters, Apple has recorded several small beats. These include 537.48% in August 06, 2024.

Shareholding & Insider Activity

Veracyte, Inc. has 78.67 million shares outstanding. The public float is 78.21 million shares, elevated short interest at 11.40% of float. This equals 8.04 million shares. The short ratio is 5.71 days. Institutional investors hold 111.68% of the float. Insiders own 1.0%. Stapley Marc holds 357.55 thousand shares, Chambers Rebecca has 131.20 thousand shares and Febbo Phillip G. has 117.35 thousand shares. Over the past six months, insider transactions show net selling. They sold 111.50 thousand shares across 20 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Veracyte generated $361.05M in revenue, or $4.97 per share. Gross margin was 61.81%, operating margin -3.34%, and net profit margin -20.61%. Returns are negative, with ROA at -6.54% and ROE at -7.13%.
On valuation metrics, Veracyte trades at a P/E of 39.18, P/S of 5.04 and P/B of 1.98. The current ratio is 8.15 and quick ratio is 7.81. Operationally, the company’s inventory turnover is 7.39 and cash conversion cycle is 69.85 days. Debt-to-equity is 0.03, supported by a cash flow-to-debt ratio of 3.44.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Veracyte posted revenue of $361.05M, down slightly from $296.54M in the prior quarter. Gross profit was $223.15M (margin 61.81%). Operating income was - $12.06M (margin -3.3%). Net income was- $74.40M (EPS - $1.02).
The company ended the quarter with $216.45M in cash and short-term investments, a total debt of $12.63M, and net debt of - $203.82M. Total assets were $1.14B, with equity of $1.04B. Financials further reflected stability, with operating cash flow of $44.22M, free cash flow of $34.26M, and capital expenditures of - $9.96M.

Price Forecast & Outlook

Our AI price prediction model suggests that Veracyte, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.4%, with price expected at $34.61 by May 06, 2026, within a range of $33.39 to $35.81 3-Month Outlook: Projected fall of -9.8%, reaching $29.90 by July 21, 2026, with a range of $28.91 to $31.12. 1-Year Outlook: Projected gain of 11.1%, with price at $36.83 by April 22, 2027, within a range of $34.71 to $38.60.

Key Takeaways

Veracyte, Inc. (NASDAQ:VCYT) shares are flat -0.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Veracyte, Inc. trading at a premium to the broader market with a P/E of 39.18. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $40.04, suggesting 20.78% upside. Our AI forecast model points to short-term strength (4.4% over two weeks), a medium-term fall (-9.8% over three months), and a longer-term gain (11.1% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Veracyte, Inc. (VCYT) stock price?

Veracyte, Inc. (NASDAQ: VCYT) stock price is $33.15 in the last trading session. During the trading session, VCYT stock reached the peak price of $33.90 while $31.96 was the lowest point it dropped to. The percentage change in VCYT stock occurred in the recent session was -1.66% while the dollar amount for the price change in VCYT stock was - $0.56.

VCYT's industry and sector of operation?

The NASDAQ listed VCYT is part of Biotechnology industry that operates in the broader Healthcare sector. Veracyte, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VCYT?

Mr. Robert Brainin
Executive Vice President & Chief Bus. Officer
Ms. Rebecca Chambers
Executive Vice President & Chief Financial Officer
Dr. Giulia C. Kennedy Ph.D.
Global Chief Scientific Officer & Chief Medical Officer
Mr. Jonathan Wygant
Vice President & Chief Accounting Officer
Ms. Bonnie H. Anderson
Co-Founder & Director
Mr. Steven French
Senior Vice President & Chief Information Officer
Mr. John Walter Hanna Jr.
Chief Commercial Officer and GM of Endocrinology, Breast Cancer & Lymphoma
Ms. Annie McGuire
Executive Vice President, Gen. Counsel & Chief People Officer
Dr. Fabienne Hermitte Ph.D.
Senior Vice President of Global Quality & Regulatory Affairs
Dr. John Leite Ph.D.
Senior Vice President and GM of Pulmonology & Market Access
Ms. Corinne Danan
Senior Vice President and GM of Biopharma & IVD Services
Ms. Tracy Morris
Vice President of Global Corporation Communications
Ms. Beverly Jane Alley CPA
Vice President & Corporation Controller
Mr. Marc A. Stapley
Chief Executive Officer & Director

How VCYT did perform over past 52-week?

VCYT's closing price is 46.62% higher than its 52-week low of $22.61 where as its distance from 52-week high of $50.71 is -34.63%.

How many employees does VCYT have?

Number of VCYT employees currently stands at 824.

Link for VCYT official website?

Official Website of VCYT is: https://www.veracyte.com

How do I contact VCYT?

VCYT could be contacted at phone 650 243 6300 and can also be accessed through its website. VCYT operates from 6000 Shoreline Court, South San Francisco, CA 94080, United States.

How many shares of VCYT are traded daily?

VCYT stock volume for the day was 829.89K shares. The average number of VCYT shares traded daily for last 3 months was 905.72K.

What is the market cap of VCYT currently?

The market value of VCYT currently stands at $2.63B with its latest stock price at $33.15 and 79.46M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	824
Beta	1.96
Sales or Revenue	$361.05M
5Y Sales Change%	1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VCYT Company Profile and Key Details

Veracyte

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook